Providing Medical Information for Orphan Drugs

被引:0
|
作者
Turbeville, Sean [1 ]
Wells, David A. [2 ]
Hornfeldt, Carl S. [3 ]
机构
[1] Onyx Pharmaceut Inc, San Francisco, CA 94080 USA
[2] Prosar, St Paul, MN USA
[3] Apothekon Inc, St Paul, MN USA
来源
DRUG INFORMATION JOURNAL | 2012年 / 46卷 / 01期
关键词
orphan drugs; rare disease; drug information; medical information; orphan drug manufacturer; MATERNAL PHENYLKETONURIA; RARE DISEASES; INDUSTRY; ACT;
D O I
10.1177/0092861511427696
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Medical information departments are responsible for providing information regarding the drugs the company manufactures and the diseases these drugs treat. The medical information departments of orphan drug manufacturers face unique challenges. Although they receive fewer inquiries, those received usually require sophisticated and time-consuming responses, often based on unpublished information and with greater reliance on rare disease experts. Worldwide distribution results in interactions with non-English-speaking individuals and requires familiarity with international legal requirements. Orphan drug medical information staff has greater visibility and is more likely to be contacted regarding adverse events and assistance for investigator-initiated clinical studies. As primary sources of information for patients, they need to be familiar with patient advocacy groups, clinical trial enrollment, and sources of unapproved medications such as expanded access programs. The ideal orphan drug medical information department is staffed with specialized health care professionals with advanced training dedicated to 1 or 2 orphan drug products.
引用
收藏
页码:88 / 93
页数:6
相关论文
共 50 条
  • [31] Authorization and Reimbursement of Orphan Drugs in an International Comparison
    Roll, K.
    Stargardt, T.
    Schreyoegg, J.
    GESUNDHEITSWESEN, 2011, 73 (8-9) : 504 - 514
  • [32] Market uptake of orphan drugs - a European analysis
    Picavet, E.
    Annemans, L.
    Cleemput, I.
    Cassiman, D.
    Simoens, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) : 664 - 667
  • [33] Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs
    James D. Chambers
    Madison C. Silver
    Flora C. Berklein
    Joshua T. Cohen
    Peter J. Neumann
    Journal of General Internal Medicine, 2020, 35 : 2629 - 2636
  • [34] Estimating the clinical cost of drug development for orphan versus non-orphan drugs
    Kavisha Jayasundara
    Aidan Hollis
    Murray Krahn
    Muhammad Mamdani
    Jeffrey S. Hoch
    Paul Grootendorst
    Orphanet Journal of Rare Diseases, 14
  • [35] Patient Access to Medical Insurance Covered Orphan Drugs in China: Real-World Evidence From Patient Survey
    Wang, Xiang
    Li, Shu-Chuen
    Yue, Xiaomeng
    Li, Yuxiang
    Shi, Ning
    Zhao, Fei-Li
    Wu, Jiuhong
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 34 : 71 - 77
  • [36] International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review
    Lasalvia, P.
    Prieto-Pinto, L.
    Moreno, M.
    Castrillon, J.
    Romano, G.
    Garzon-Orjuela, N.
    Rosselli, D.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (04) : 409 - 420
  • [37] Orphan Drugs from the Perspective of the Drug Commission of the German Medical Association Opportunities and Challenges
    Ludwig, Wolf-Dieter
    INTERNIST, 2019, 60 (04): : 399 - 404
  • [38] Implementation status of pharmacological studies in the development of orphan drugs
    Yokoshiki, Saki
    Arato, Teruyo
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [39] Analysis of the real availability of the orphan drugs in the Slovak Republic
    Kuzelova, M.
    Ondriasova, E.
    Foltanova, T.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (02) : 406 - 407
  • [40] Affordable orphan drugs: a role for not-for-profit organizations
    Davies, Elin H.
    Fulton, Emma
    Brook, Daniel
    Hughes, Dyfrig A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (07) : 1595 - 1601